GTx Announces Presentation of Ostarine and Acapodene Data at 2007 ASCO Annual Meeting
MEMPHIS, Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc., (NASDAQ: GTXI) announced today that data from the recent Phase II proof of concept clinical trial of Ostarine(TM) and from the ongoing Phase III clinical trial evaluating ACAPODENE(R) (toremifene citrate) 80 mg for the treatment of multiple...New Report Just Published: World Prostate Cancer Therapeutics Market Report
...by Entering into Spain II-82 Altana Divests Entire Stake in GPC Biotech II-83 Ipsen Enters into Partnership with GTx to Develop and Market acapodene in Europe II-83 Egenix and Proteome Systems Collaborate to Develop Prostate Cancer Test Using Semen II-83 Valera and Spepharm Partner to M...Flexyx: Acapodene (Generic name - Toremifene) OnLine Information
Acapodene (Generic name - Toremifene) OnLine Information - A first generation selective estrogen receptor modulator (SERM). Like tamoxifen, it is an estrogen ...News: GTx, Inc. Reports Third Quarter 2006 Financial Results.
GTx, Inc. (NASDAQ: GTXI), the Men's Health Biotech Company, today reported ... Second, GTx retains exclusive rights to ACAPODENE(R) in the United States, where ...Pivotal Phase III Acapodene Trial Begins For The Prevention Of Prostate ...
ACAPODENE is a nonsteroidal SERM (selective estrogen receptor modulator), a ... citrate, the active ingredient of ACAPODENE tablets, in all indications in the ...Development On Track at GTx - Morningstar Stock Analyst Notes
Development On Track at GTx - <P>We are maintaining our fair value estimate for GTx <a href=http: ... GTx expects to hear back on Acapodene by late October. ...